منابع مشابه
Rotigotine transdermal system: a short review
Rotigotine (Neupro((R))) is a new non-ergolinic dopamine agonist transdermal patch that can be applied once daily. To date, it is approved for the treatment of early Parkinson's disease as monotherapy and has been shown to be effective in the treatment of advanced-stage Parkinson's disease and restless legs syndrome in several clinical trials. This review gives an overview of physical, chemical...
متن کاملBehavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
Effective therapies for the so-called atypical parkinsonian syndrome (APS) such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal syndrome (CBS) are not available. Dopamine agonists (DA) are not often used in APS because of inefficacy and in a minority of case, their side effects, like dyskinesias, impairment of extrapyramidal symptoms or the appearance of ...
متن کاملRotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
The main clinical features of Parkinson’s disease are tremor, muscular rigidity, akinesia (inability to move), and postural instability. Other features of the disease include changes in gait, mask-like face, micrographia (progressively smaller handwriting), and psychiatric symptoms; depression occurs in 50% of patients over the course of their illness. The diagnosis is made by clinical symptoms...
متن کاملTransdermal rotigotine for the perioperative management of restless legs syndrome
BACKGROUND Immobilisation, blood loss, sleep deficiency, and (concomitant) medications during perioperative periods might lead to acute exacerbation of symptoms in patients with the restless legs syndrome (RLS). Continuous transdermal delivery of the dopamine agonist rotigotine provides stable plasma levels over 24 h and may provide RLS patients with a feasible treatment option for perioperativ...
متن کاملRotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome
Rotigotine, a nonergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMA and FDA marketing authorization for the treatment of adult patients with early or advanced Parkinson’s disease or with moderate-to-severe restless legs syndrome (RLS). This review comprises an overview of the pharmacokinetics, the pharmacodynamics and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Neurology
سال: 2007
ISSN: 0003-9942
DOI: 10.1001/archneur.64.5.676